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Aldosterone receptor blockersThe aldosterone receptor blocker therapy as an “add-on” to hypotensive therapy is an excellent therapeutic strat-
egy that has proved to beparticularly effective in treating refractory hypertension, hypertensionwith organ dam-
age and overweight hypertensive patients. Aldosterone receptor blockers are extremely useful in inhibiting
hormonal activation linked with heart failure: they have cardioprotective effects not only during full-blown
heart failure, but also in its early stages, and this effect can be observed even more frequently in heart failures
with metabolic syndrome. The use of molecules such as canrenone with a favorable tolerability proﬁle ensures
a better tolerability ratio by providing beneﬁts linked to fewer drug interactions, lower incidence of side effects
and improved therapy adherence.
© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND 4.0 license
(http://creativecommons.org/licenses/by/3.0/).1. Aldosterone receptor blocker and hypertension: why, when?
One of the main challenges of modern medicine is to achieve an ad-
equate monitoring of the population's blood pressure: despite multiple
therapeutic choices; in fact, current data show that a large proportion of
patients do not reach target blood pressure.
Recent observations are not encouraging: in the US less than 50% of
patients undergoing hypertensive treatment reach the target and the
percentage is even lower in high risk patients [1]. A recent study carried
out by Dr. Volpe in Italy on 50,000 subjects in several Italian regions, has
proved how in treated patients, only 1/5 of the hypertensive ones
arrives at pressure values b140/90 mm Hg and, among these, only half
the cases reached the target blood pressure [2].
This phenomenon needs to be explained. The recent European
Guidelines on Arterial Hypertension [3,4] have introduced the concept
of Resilient Hypertension, i.e. the failure of target blood pressure despite
the administration of at least three drugs including a diuretic and an
adequate change in life style. The causes that can explain this state of
things aremultiple: inter alia an important role is played by poor adher-
ence to therapy, inadequate modiﬁcation of lifestyle, a concomitant
drug administration that may lead to blood pressure increase as in
glucocorticoids and NSAIDs (non-steroidal anti-inﬂammatory drugs),
also associated with obstructive sleep apnea syndrome.
A decisive role is deﬁnitely represented by an overload of volume
due to inadequate diuretic therapy, progressive renal failure, increase
of sodium intake and presence of high aldosterone values. In recent
years there has been abundant evidence of the role of aldosterone in
the development of arterial hypertension. One of the main effects isis an open access article under the Chypervolemia which is linked to the increase in the reabsorption of
sodium and water, as well as augmented kidney level [5].
Furthermore, aldosterone induces the formation of collagen in the
heart as well as in the peripheral vessels with a consequent remodeling
of tissue and increase in peripheral vascular resistance. Besides that, it
alters the endothelial function and by binding itself to the smooth vas-
cular muscle receptors, it may alter the pressure response to adrenergic
stimulation.
It is interesting to observe how aldosterone levels are connected to
the severity of sleep apnea syndrome in patients with obstructive sleep
apnea, a condition that has been underestimated for years and is now
considered one of the most common causes of resistant hypertension.
Over the years, knowledge of the harmful role of aldosterone has
meant that themain therapeutic strategies against hypertension control
were based on an Angiotensive Renin Aldosterone system, using drugs
such as ACE inhibitors, ARBs, andmore recently, Renin inhibitors. How-
ever, the modulation of such a system is often insufﬁcient: several clin-
ical trials have in fact underlined that after an initial reduction of the
aldosterone levels during the administration of ACE-I, after a period of
time from 3 to 12 months, the plasma levels of the hormone tend to
rise again. This phenomenon, known as aldosterone “Escape” is evident
bothwith the ACE-I inhibitors aswell aswith the Angiotensin Receptive
Blockers (ARBs) and can also take place during the double block of the
RAA system with ACE and ARBs. The extent of the phenomenon is not
negligible: several studies have proved that the escape is present in
over 40% patients treated with ACE and/or ARBs (Fig. 1).
The causes of this phenomenon aremultiple: an important role is cer-
tainly played by the production of angiotensin II. Through mechanismsC BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1.
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tensin I in the brain, heart and blood vessels through non-ACE paths
and contributes to the production of aldosterone. There is also evidence
that the “Escape” of aldosterone in turn may promote the release of
angiotensin II through a feedback control that stimulates ACE in the
blood vessels.
Furthermore, the phenomenon can also occur in the absence of a rise
in angiotensive II because of alternative stimuli to angiotensin which
induce the production of aldosterone. These stimuli include increased
K+ induced by ACE-I, ACTH, adipokines and vasopressin (Fig. 2).
On the basis of these ﬁndings both the pathogenic role played by al-
dosterone receptor blockers in the development of resistant hyperten-
sion, and the rationale of the therapy with drugs that are antagonists
of the aldosterone receptors when dealing with this clinical reality are
evident.
A growing number of studies conﬁrm the antihypertensive effective-
ness of aldosterone receptor blocker in addition to treatment with ACE-I
or ARBs with or without thiazide in resistant hypertension. The mean
dosage prescribedwas 50mg/day. The results of the studies demonstrat-
ed a signiﬁcantly greater control of pressure values (with a decrease inFig. 2.PAS approximately equal to 22 mm Hg and DBP of 10 mm Hg), which
was obtained only when the drug “added”was the aldosterone receptor
blockers and not another class of hypotensives. The addition of aldoste-
rone receptor blockers is therefore a rational therapeutic choice in
patients with uncontrolled hypertension (Fig. 3) [7].
To this end, the ESCAPE study (Efﬁcacy and Safety of Canrenone Add
on in Patients With Essential Hypertension) was designed and is still in
progress to deﬁne the therapeutic efﬁcacy, tolerability and safety of the
use of aldosterone receptor blocker canrenone in addition to therapy
with ACE-I or ARBs and diuretics in patients with uncontrolled hyper-
tension comparing two different doses of canrenone, 50 mg/day versus
100 mg/day.
Patients included were hypertensive outpatients, aged between
45 and 75 years of age, with uncomplicated hypertension and BP
values N140.90 mm Hg but b180/100 despite therapy with ACE-I/
ARBs and diuretics. Begun in 2011, the study will end in the ﬁrst half of
2012. Canrenone treatment for each patient is scheduled for 3 months.Fig. 3.
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offersmany advantages, in addition to a simple but highly effective con-
trol of blood pressure, as it can ensure greater protection against organ
damage both at the kidney and at the cardiac level. And it is precisely
upon the possibility of a greater protection of organs that the attention
of many researchers has recently concentrated. In the kidneys the
addition of an aldosterone receptor blocker with ACE-I and/or ARBs in
hypertensive patients with diabetic nephropathy induced a signiﬁcant
reduction of proteinuria up to 60% with signiﬁcant improvement of
renal function. Signiﬁcant data on left ventricular hypertrophy were
also highlighted: the addition of an aldosterone receptor blocker in
hypertensive patients treated with ACE or ARBs induced an important
reduction of left ventricular hypertrophy both as a mass of the left
ventricular as well as an index of the left ventricular mass [8].
The use of an aldosterone receptor blocker therapy in hypertension
appears therefore particularly suitable both in hypertension resistant
to treatment as when the intent is to ensure a greater renal and heart
protection.
The possibility of using an aldosterone receptor blocker in phar-
maceuticals as a ﬁrst-line drug in patients with uncomplicated hy-
pertension was also evaluated; in a study, White and colleagues
have compared 267 hypertensive patients with isolated systolic hyper-
tension who assumed aldosterone receptor blockers e (50–100 mg/day)
and amlodipine (2.5–10 mg/day). The main objective consisted of
demonstrating the non-inferiority of the aldosterone receptor blocker
therapy with a reduction in SBP to be reached in 24 months [9]. There-
fore, there may be a case for the use of aldosterone receptor blockers in
patients treatedwith a single drugwho do not reach the target pressure
or, in selected cases, that can interact with the mechanisms leading to
organ damage, such as a front-line class drug.
A typical candidate for effective treatmentwith aldosterone receptor
blockers as a front-line drug is the overweight hypertensive patient. As
is known, obesity and overweight have a high incidence in the popula-
tion (about 50% of men and 34% of women aged between 35 and
74 years are overweight, and about 17% of men and 21% of women are
obese); this phenomenon weighs particularly on hypertensive patients
(about 70% of hypertensive patients are overweight, 30% obese). The
probability of an inadequate control of blood pressure in obese patients
is approximately 50% higher compared with normal-weight patients.
Overweight and obesity are associatedwith an increased production
of aldosterone receptor blockers; this production comes primarily from
adipose tissue, which is mostly visceral: the adipokines released by
adipocytes stimulate the secretion of aldosterone receptor blockers,
regardless of the RAA system (Fig. 4) [10,11].Fig. 4.Some studies have shown that the bodymass index (BMI) is directly
related to the plasma concentration of aldosterone. It has been demon-
strated that the effectiveness of aldosterone receptor blockers in terms
of improved blood pressure control is even more signiﬁcant in the
overweight/obese patient .
2. Aldosterone receptor blockers as a cornerstone in the treatment
of heart failure: is there something new?
The close correlation of neuro-hormonal activation with the
progression of heart failure is well known; at the end of the 1990s, the
results of the now historic RALES trial (1663 patients in NYHA classes
III–IV treated with spironolactone had a reduction in total mortality of
30%) showed that aldosterone receptor blockers led to a signiﬁcant
beneﬁt in terms of mortality and morbidity in heart failure.
Subsequently the EPHESUS study evaluated the effects of eplerenone
(a selective aldosterone blocker) in patients with left ventricular
dysfunction after MI, showing net beneﬁts in terms of a signiﬁcant re-
duction of total mortality (−15%) and mortality and cardiovascular
hospitalization (−13%) [12].
The blocking effects of aldosterone appeared therefore particularly
useful in mild heart failure in which prevention of ventricular remodel-
ing is decisive.
This was the basis upon which the AREA IN CHF study was planned
to evaluate the addition of canrenone to optimal therapy in patients in
NYHA class II: canrenone induced a signiﬁcant increase in ejection frac-
tion, a reduction in left ventricular mass and a reduction in the size of
the left atrium. Concomitant clinical improvement in terms of reduction
of mortality, hospital admissions and an improvement in NYHA class
(22% of patients fell into class I in the canrenone group compared to
13.2% in the placebo group) [13,14].
In 2011 the EMPHASIS HF study deﬁnitively conﬁrmed the advan-
tage of the effect of adding eplerenone to optimal therapy in patients
with heart failure NYHA class II: the studywas prematurely interrupted
because of a signiﬁcant reduction in cardiovascular mortality and
hospitalization for heart failure in the group treated, compared to the
placebo group (−37%, p b 0.001) [15].
Recently, the ﬁnding of a correlation between heart failure, aldoste-
rone and metabolic syndrome, which is expressed in the frequent ﬁnd-
ing of high levels of aldosterone in the metabolic syndrome has created
particular interest: in particular a correlation between aldosterone
levels and insulin resistance which is, in turn, very frequently present
in patients with heart failure [16,17].
In the metabolic syndrome, an increase of visceral adipose tissue
induces the production of aldosterone receptor blockers via both
angiotensin II as well as independently of angiotensin II.
Thus, elevated levels of aldosterone receptor blockers induce both
the preservation of chronic inﬂammatory states as well as the worsen-
ing of insulin resistance in the metabolic syndrome.
Can aldosterone receptor blockers combat this phenomenon?
A substudy of the AREA IN CHF evaluated the effect of an addition of
canrenone in patients with mild heart failure (NYHA II) and metabolic
syndrome. In this subgroup of patients canrenone had a beneﬁcial effect
on the energy proﬁle of the infarction: the efﬁciency of the mechanical
energy of the myocardium (measured by the ratio of stroke volume
and cardiac cycle) was preserved and even improved [18].
In conclusion aldosterone receptor blockers play a cardioprotective
role not only in the phases of heart failure, but also in the early stages
(from dysfunction to mild HF) and this effect is even more frequent in
decompensated patients with metabolic syndrome.
3. Aldosterone receptor blockers: safety and tolerability
The major side effects of aldosterone receptor blockers are
hyperkalemia and gynecomastia: we must however clarify ﬁrstly that
these effects are dose dependent, especially concerning gynecomastia,
Fig. 5.
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available.
The use of aldosterone receptor blockers is often associated with an
increase in the values of serum potassium: this phenomenon is related
to the same mechanism of the drug and can be considered a planned
class effect. However evident cases of hyperkalemia (N5.5 mEq/L) are
infrequent: in particular, they are equally about 4% without associated
diuretics and 2.6% associated with diuretics. The studies conducted in
patients with heart failure showed a moderate increase in the values
of hyperkalemia: in RALES values of potassium N5.5mEq/Lwere report-
ed in 2% of patients treated with spironolactone, compared with 1% ob-
served in the control group (Fig. 5) [19]; in the EMPHASIS-HF trial, 2.5%
in the eplerenone group and 1.9% in the placebo group (p n.s.) [15].
In the IN-CHF area, hyperkalemia was observed in 1.3% during
treatment with canrenone, while in the placebo group, the percentage
was 0.85% (p n.s.) [13].
It must also be remembered that in any case, an increase in serum
potassium was not associated with a higher incidence of mortality.
Gynecomastia is a troublesome side effect that often reduces the
compliance to treatment and is present in very different percentages
according to the molecules: 10% spironolactone, 0.8% for canrenone.
The spironolottane has an afﬁnity for the androgen and progestin re-
ceptors, and can also interferewith steroid biosynthesis through the inhi-
bition of cytochrome P450. These mechanisms can cause gynecomastia,
tenderness and breast pain, menstrual irregularities and decreased
libido inwomen, and impotence inmen. Canrenone is the activemetab-
olite of spironolactone and does not require hepatic metabolism; it
exerts its action more quickly and by not using the cytochrome 450, it
has a lower frequency of drug interactions. A lower anti-androgenic
effect rarely induces hormonal type side effects.
4. Conclusions
Aldosterone plays a pivotal role in the progression of cardiovascular
disease, from arterial hypertension to heart failure.
The majority of hypertensive patients are not controlled, and an
“actor” in the lack of control is the escape from aldosterone. The
aldosterone receptor blocker in “add-on” to therapy offers excellenteffectiveness even at low doses: good tolerability and major organ
protection. This therapeutic strategy appears to be particularly effec-
tive in refractory hypertension, hypertension with organ damage
and in overweight hypertensive patients.
The aldosterone receptor blocker drugs are extremely useful in
countering the hormonal activation in heart failure: they act as
cardioprotectors not only in overt heart failure, but also in its early
stages (from mild dysfunction to heart failure), and this effect is even
more frequent in decompensated patients with a metabolic syndrome.
The use ofmolecules such as canrenone, with a favorable tolerability
proﬁle, ensures a better efﬁcacy/tolerability ratio, offering advantages
related to minor drug interaction, lower incidence of side effects and a
greater adherence to therapy.Conﬂict of interest
The authors report no relationships that could be construed as a
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